July 2026 Research Update

This month brought a clearer answer on carbetocin nasal spray for hyperphagia in Prader-Willi syndrome: in a phase 3 study, the medication and placebo improved by similar amounts, so there was no meaningful difference between groups. That matters because this trial was designed to test whether carbetocin can measurably change food-seeking symptoms over 12 weeks, and it did not show that separation.

In 175 participants, the main hyperphagia score (HQ-CT) changed similarly in the carbetocin and placebo groups at week 12, and the same lack of separation was seen on the other clinician-rated and exploratory measures included in the trial. The most common side effects reported with carbetocin were headache and fever, without other safety patterns described in the summary.

For families looking for medication options to help with hyperphagia, this study mainly adds clarity rather than a new option: carbetocin nasal spray did not show a benefit beyond placebo on the trial's hunger-related scales over 12 weeks. The results are strong as evidence about what happened in this specific study period, but they do not answer whether different dosing, longer follow-up, or specific subgroups might respond differently, because those details are not established here.

Several studies this month focused on how Prader-Willi syndrome affects thinking skills and behavior, and the overall picture was that cognitive and self-control skills are commonly affected but do not look the same in every person. These studies also suggest that some challenges (like skin picking) may not neatly "go together" with other behavior or sensory measures, which may help explain why day-to-day support needs can vary a lot across individuals. [1] [2] [3]

In children aged 9 to 15, one study found clear differences from peers in cognitive and executive function (skills like planning, flexible thinking, and self-control) and more emotional or affective problems. It also identified three behavioral-emotional profiles, including groups with mainly cognitive/executive difficulties, mainly affective difficulties, or relatively more preserved skills, and these profiles did not differ in reported family impact in that dataset. [1]

A separate study comparing Prader-Willi genetic subtypes reported exploratory signals that the mUPD subtype may have greater difficulties in executive control, processing speed, and understanding other people's thoughts and feelings. Within the mUPD group, preliminary links were also reported between psychosis-related markers and specific thinking patterns such as reduced flexibility and a more self-focused interpretation style, but the authors described these as early findings needing confirmation. [4]

For skin picking, a study in 65 people found that severity varied but did not show a clear relationship with sensory processing scores or broader maladaptive behavior scores, and it also did not differ by genetic subtype. In plain terms, skin picking may be a somewhat independent feature in PWS rather than simply a byproduct of sensory sensitivities or overall behavior severity as measured in this study. [3]

One additional study connected body and hormone differences with thinking and appetite measures, reporting that children and teens with PWS had more body fat, higher hyperphagia scores, and lower memory scores than comparison groups. In that study, several hormone and metabolic measures tracked with appetite, body fat, and memory within the PWS group, but because the data were collected at one point in time, it cannot show which factors cause which outcomes. [2]

Taken together, these studies support a practical idea many families already recognize: difficulties with self-control skills and memory are common in PWS, but people can show different patterns, and not every challenge is tightly linked to every other one. This mainly matters now for understanding and communication, because it reinforces that a single label like "behavior problems" can hide different underlying difficulties (for example, executive skills versus mood-related symptoms), and it also points to areas that research is trying to measure more precisely. What remains uncertain is how stable these profiles are over time and whether the subtype-related signals for psychosis risk markers in mUPD will hold up in larger groups.

This month added a mix of real-world observations and early-stage biology studies that help fill in the "how does PWS affect the body" picture, but mostly as groundwork rather than immediate changes. The studies collectively highlight that some important issues (like bowel symptoms) may be under-recognized, and that research is still mapping which genes and body systems contribute to sleep, development, and PWS-like conditions. [5] [6] [7] [8]

In a chart review plus caregiver questionnaire from a specialty clinic, 17% of children and young adults met criteria for functional constipation, and 35% reported stooling accidents after toilet training. Older age and more laxative use were linked with meeting constipation criteria, and caregiver impression did not reliably match the questionnaire-based definition, suggesting constipation may be missed without structured questions. [5]

On the diagnosis side, two siblings with a Prader-Willi-like presentation were found to have a homozygous TRAPPC9 mutation, expanding the known genetic causes that can resemble PWS. This matters because it shows why genetic testing can be important when a person looks like they have PWS but standard PWS testing does not fit, although this report does not address how common this cause is. [6]

Two mouse studies added early signals about specific PWS-region genes and body functions. In one, deleting Snord116 increased REM sleep in mice, while deleting Snord115 alone did not, and deleting both together unexpectedly removed the Snord116 REM-sleep change; this was accompanied by fewer MCH neurons in the hypothalamus. [7]

In another mouse model with a broader PWS deletion, the placenta showed reduced expression of several PWS genes and about a 25% reduction in a type of fetal blood-vessel cell in the placenta, without a clear late-gestation growth difference. This raises the possibility that placental changes could contribute to later features, but it is still animal research and does not show what happens in human pregnancies. [8]

For day-to-day life, the constipation study may matter the most right now because it quantifies how often bowel symptoms and accidents were reported in one clinic group, and it shows that casual impressions may miss constipation when structured criteria are applied. The genetics and mouse studies mainly matter for the future: they refine the map of conditions that can look like PWS and explore how specific genes might affect sleep and early development, but they do not translate directly into specific care actions. Important uncertainties remain about how well the mouse findings reflect human PWS and how frequently TRAPPC9-related PWS-like syndrome occurs in broader populations.

This month included several single-patient reports that do not tell how common an issue is, but they show the range of situations that can occur alongside or be mistaken for Prader-Willi syndrome. The shared message is that genetics and long-term multidisciplinary follow-up can become especially important when the medical course is complex or when more than one condition is present. [9] [10] [11]

One report described a girl with genetically confirmed PWS who developed medulloblastoma and then experienced significant endocrine and metabolic complications during and after cancer treatment, including ongoing growth hormone deficiency, thyroid and adrenal problems, insulin resistance, and severe obstructive sleep apnea requiring CPAP. The report also described a later tumor recurrence and an eventual death in childhood, emphasizing this was an unusually severe and complex course rather than a typical PWS pathway. [9]

Another report described a 7-year-old girl in Nigeria with PWS due to maternal uniparental disomy confirmed by genetic testing, including early feeding problems followed by later obesity and strong appetite. The case noted a 3 kg weight reduction over 8 months during lifestyle changes, and it highlighted challenges in access to diagnostic resources. [10]

A separate genomic case report described a person with a PWS-related imprinting finding (maternal UPD(15)) plus an additional inherited deletion affecting NR5A1, a gene linked to differences in sex development. This shows how more than one genetic condition can contribute to a person's overall health picture, especially when symptoms extend beyond what is usually expected for PWS. [11]

For patients and caregivers, these case reports mainly add context rather than general rules: they show that rare combinations (like a brain tumor or a second genetic diagnosis) can complicate the usual PWS experience, and that diagnostic clarity can matter when the presentation is atypical. Because each report is a single person (or a single family), the findings cannot be used to estimate risk for others, but they can help families recognize why care teams sometimes pursue broader genetic workups or closer monitoring when the situation does not fit the usual pattern.